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Background: Abelmoschus manihot, a single medicament of traditional Chinese medicine, has been widely
used to treat kidney disease. This is the first randomized controlled clinical trial to assess its efficacy and safety
in patients with primary glomerular disease.
Study Design: Prospective, open-label, multicenter, randomized, controlled, clinical trial.
Setting & Participants: From May 2010 to October 2011, a total of 417 patients with biopsy-proven primary
glomerular disease from 26 hospitals participated in the study.
Interventions: A manihot in the form of a huangkui capsule, 2.5 g, 3 times per day; losartan potassium,
50 mg/d; or combined treatment, a huangkui capsule at 2.5 g 3 times per day, was combined with losartan
potassium, 50 mg/d. The duration of intervention was 24 weeks.
Outcomes & Measurements: The primary outcome was change in 24-hour proteinuria from baseline after
treatment. Change in estimated glomerular filtration rate (eGFR) from baseline after treatment was a
secondary outcome. The 24-hour proteinuria was measured every 4 weeks and eGFR was measured at 0,
4, 12, and 24 weeks.
Results: Mean baseline urine protein excretion was 1,045, 1,084, and 1,073 mg/d in the A manihot, los-
artan, and combined groups, respectively, and mean eGFR was 108, 106, and 106 mL/min/1.73 m2,
respectively. After 24 weeks of treatment, mean changes in proteinuria were protein excretion of 2508, 2376,
and 2545 mg/d, respectively (P 5 0.003 for A manihot vs losartan and P , 0.001 for the combined treatment1Department of Nephrology, State Key Laboratory of
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58vs losartan). Mean eGFR did not change significantly. The incidence of adverse reactions was not different
among the 3 groups (P . 0.05), and there were no severe adverse events in any group.
Limitations: Results cannot be generalized to those with nephrotic syndrome or reduced eGFR.
Conclusions: A manihot is a promising therapy for patients with primary kidney disease (chronic kidney
disease stages 1-2) with moderate proteinuria.
Am J Kidney Dis. 64(1):57-65. ª 2014 by the National Kidney Foundation, Inc.
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Este é um artigo Open Access sob a licença de CC BY-NC-NDChronic kidney disease (CKD) is a common dis-ease that affects 11% of the total population.1
Primary glomerular disease is the most common type
of CKD and the leading cause of end-stage kidney
disease in China.2 Effective control of proteinuria may
be an important strategy for treating CKD.3,4 Renin-
angiotensin-aldosterone system blockers, glucocorti-
coids, and immunosuppressants commonly are used
for primary glomerular diseases. Immunosuppressive
therapies have been used mainly to treat patients
with heavy proteinuria and are not entirely suitable
for patients with non–nephrotic-range proteinuria.
Furthermore, treatment with glucocorticoids and im-
munosuppressants usually requires a long duration of
treatment, which can cause severe adverse effects
and increases the potential for rebound.5,6 There-
fore, exploring additional therapeutic strategies for
patients with minor- to moderate-range proteinuria is
necessary.
Traditional Chinese medicine has shown promising
effects on the control of proteinuria, protection of
kidney function, and improvements in patients’ clin-
ical symptoms.7,8 Abelmoschus manihot is a tradi-
tional Chinese medicine that has become increasingly
used in a variety of types of CKD, such as immuno-
globulin A (IgA) nephropathy (IgAN), membranous
nephropathy, and diabetic nephropathy.9-12 Clinical
studies have shown that A manihot can reduce pro-
teinuria and protect kidney function.11,13,14 However,
most clinical trials of A manihot for the treatment of
CKD involved small samples and had a low level of
clinical evidence. Previous studies reported that
angiotensin II receptor blockers (ARBs) reduce pro-
teinuria and give extra renoprotective effects beyond
those from blood pressure control in patients with
CKD.15-17 Losartan is one of the commonly used
ARBs and its beneﬁts have been conﬁrmed by several
clinical trials in CKD.18,19 Thus, we chose losartan as
the active control drug. We hypothesized that A
manihot was noninferior to losartan and the combined
treatment of losartan and A manihot was superior to
losartan alone in reducing proteinuria. To test this
hypothesis, we conducted a prospective, multicenter,
randomized, controlled, clinical trial to evaluate the
efﬁcacy and safety of A manihot in treating primary
glomerular disease.METHODS
Trial Design
This study was a multicenter open-label randomized trial con-
ducted in 26 hospitals across China. The study protocol was
designed by members of the executive committee (composed of
individuals from the Chinese People’s Liberation Army General
Hospital, First Afﬁliated Hospital of Nanjing Medical University,
and Second Afﬁliated Hospital of Dalian Medical University).
This study was approved by the Medical Ethics Committee of the
Chinese People’s Liberation Army General Hospital. Patients were
divided into an A manihot group, losartan group, and combined
treatment group. Approximately 420 patients were to be randomly
assigned at a 1:1:1 ratio (140 patients per group). All enrolled
patients provided written informed consent. The full trial protocol
can be accessed from the Chinese People’s Liberation Army
General Hospital.
Participants
The process of recruiting participants was based on medical
record review. All hospitalized patients having a kidney biopsy
from July 2010 to March 2011 and patients with a documented
history of primary glomerular disease by kidney biopsy within
1 year were screened. Inclusion criteria were as follows: (1)
diagnosis of primary glomerular disease by kidney biopsy within
1 year; (2) aged 18-70 years; (3) blood pressure # 130/80 mm Hg;
(4) diagnosis of CKD stages 1-2, deﬁned by 2 points: estimated
glomerular ﬁltration rate (eGFR) $ 60 mL/min/1.73 m2 (calcu-
lated with the 4-variable MDRD [Modiﬁcation of Diet in Renal
Disease] Study equation as per the 2002 NKF-KDOQI [National
Kidney Foundation–Kidney Disease Outcomes Quality Initiative]
CKD guideline20) and 24-h proteinuria with protein excretion
range of 0.5w2.0 g; and (5) agreement to participate and signed
informed consent. Exclusion criteria were as follows: (1) sec-
ondary glomerular diseases; (2) history of A manihot and an
angiotensin-converting enzyme inhibitor and/or ARB used within
1 month; (3) history of glucocorticoids, immunosuppressants, or a
Tripterygium drug used for more than 3 months; (4) severe heart,
brain, liver, or hematopoietic system disease or other serious ill-
nesses that affect survival; (5) pregnancy or lactation; (6) allergy
to A manihot or losartan potassium; (7) history of alcohol or
drug abuse; and (8) participation in another clinical investigation.
Exit criteria were as follows: (1) exacerbations: proteinuria
increased one-fold compared with baseline values or protein
excretion $ 3.5 g/24 h, or doubling of serum creatinine level
or $5 mg/dL; (2) serious adverse events: hospitalization (initial or
prolonged), disability or permanent damage, life-threatening con-
dition, death, congenital anomaly/birth defect, and other serious
events (important medical events)21; (3) serious breach of proto-
col: participants not taking medications according to protocol or
taking some drugs that have a signiﬁcant impact on the primary
and secondary outcomes during the 24-week observation period;
(4) loss to follow-up or withdrawal from the trial; and (5) preg-
nancy during the trial.Am J Kidney Dis. 2014;64(1):57-65
RCT of Abelmoschus manihotData Collection
The clinical investigators ﬁlled in the case report forms, and the
inspectors reviewed the data. All data were transferred to the data
statistical units for data entry and management with the EpiData,
version 3.1, database. The database was locked by the principal
investigator, sponsor, and data analysts on October 14, 2011. After
the data lock, 10% of case report forms were extracted to check the
error rate. The error rate of the primary efﬁcacy requirements end
point was 0%, and the other error rates of the indicator re-
quirements were ,0.05%.
Interventions
Drug Names, Sizes, and Doses
A manihot: huanghui capsule (Jiangsu SuZhong Pharmaceutical
Group Co Ltd), 0.5 g 3 30 capsules/box. A huangkui capsule is a
single plant drug extract of Flos Abelmoschus manihot. Content:
dry extract (powder), 80%; magnesium stearate, 3%; and calcium
hydrogen phosphate, 17%. The medicinal parts are the corolla with
stamens and style. The plant is picked in early August to late
October (ﬂowering period), undergoes alcohol extraction into
ambrette ﬂuid extract, and then is vacuum dried and crushed into a
dry extract powder. Pharmaceutical preparation does not involve
boiling.
Losartan potassium (Hangzhou MSD Pharmaceutical Co Ltd),
50 mg 3 7 capsules/box.
Test Groups
In the A manihot group, a huangkui capsule was given orally at
2.5 g 3 times per day after meals. In the losartan group, a losartan
potassium tablet was given orally at 50 mg/d in the morning. In the
combined treatment group, a huangkui capsule was given orally at
2.5 g 3 times per day after meals, and a losartan potassium tablet
was given orally at 50 mg/d in the morning.
Treatment was continued for 24 weeks. Patients with blood
pressures . 130/80 mm Hg after treatment were given calcium
channel blockers. Appropriate treatment also was given when
patients developed hyperlipidemia, infection, or a hypercoagu-
lable state. Glucocorticoids and immunosuppressive agents were
prohibited.
Outcomes
The primary outcome was change in 24-hour proteinuria from
baseline after treatment. For this measurement, patients were
instructed to collect urine over 24 hours (from 7:00 AM to 7:00 AM
the next day), noting collection times. A medical ﬂask was used to
measure urine output and record the total amount. After stirring,
10 mL of urine was preserved at 240C. Concentration was
measured using the biuret method (Siemens; ADVIA 2400
biochemical analyzer), and 24-hour urinary protein excretion was
calculated based on concentration and 24-hour urine volume.
Secondary outcome measures included change in eGFR and serum
creatinine values from baseline after treatment. Sarcosine oxidase
was used to assay serum creatinine (Roche cobas 8000 biochem-
ical analyzer). All urine and blood samples were delivered to a
central laboratory within 4 weeks for testing.
Safety
Safety evaluation included patients’ general condition, inci-
dence of adverse events, and laboratory assessments (red blood
cell count, white blood cell count, platelet count, hemoglobin
level, alanine aminotransferase level, aspartate aminotransferase
level, triglyceride level, cholesterol level, and low-density lipo-
protein level). Adverse events and serious adverse events were
deﬁned according to the deﬁnitions of “good clinical practice” by
the China Food and Drug Administration.21 Potential adverse
events included dizziness, gastrointestinal discomfort, rash,Am J Kidney Dis. 2014;64(1):57-65itching, amenorrhea, and cough. Adverse events were recorded
every 4 weeks from the baseline visit until the ﬁnal visit. Serious
adverse events were recorded up to 30 days after the ﬁnal visit.
Follow-up Measurements
Participants were seen every 4 weeks for assessment of clinical
condition, blood pressure, adverse events, and treatment adher-
ence. The 24-hour proteinuria was measured every 4 weeks during
the 24-week trial, and blood samples were obtained at 0, 4, 12, and
24 weeks for measurement of hemoglobin, red blood cell count,
white blood cell count, platelet count, alanine aminotransferase,
aspartate aminotransferase, serum urea nitrogen, serum creatinine,
serum albumin, and blood lipids.
For measuring blood pressure, patients were seated for at least
5 minutes, relaxed and not moving or speaking before measure-
ments. The arm was supported at the level of the heart and no tight
clothing constricted the arm. Measurements were taken twice for
each patient by mercury sphygmomanometer, and average values
were used for analysis.
Sample Size Determination
Sample size determination was based on the primary outcome
and had 2 separate hypotheses. Regarding the multiple testing
issue, a level for each test was set to a 2-sided value of 2.5%. We
assumed that the expected decline in 24-hour proteinuria in the
losartan group was 400 6 150 (standard deviation) mg. With a
20% dropout rate, to enroll 130 patients per arm would offer 90%
power to demonstrate noninferiority of A manihot compared to
losartan with a 75-mg noninferiority margin (one-half of the
estimated standard deviation). The same sample size also had
99.3% power to detect a 100-mg proteinuria difference between
the combined treatment versus losartan alone. That means if
the assumed change in 24-hour proteinuria in the combined
treatment group was .500 mg, the superiority conclusion would
be achieved.
Randomization
At the coordinating center, consecutive numbers were assigned
to each hospital according to a center-stratiﬁed random order
generated by SAS Proc Plan (SAS Institute Inc). The hospitals
then randomly assigned patients to 1 of the 3 treatment groups.
Statistical Methods
Categorical variables are presented as count with percentage and
compared by c2 test or Fisher exact test. Continuous variables are
presented as mean 6 standard deviation and compared by analysis
of variance, and then the pairwise comparison was carried out. An
analysis of covariance model was used for the comparison of
changes in 24-hour proteinuria, with 95% conﬁdence intervals
estimated from mean differences 6 1.96 standard error. Statistical
analyses were performed using SAS, version 9.1.3. Data analysis
followed the principles of intention-to-treat analysis. The full
analysis set was deﬁned as all randomly assigned patients with
both a baseline and postbaseline assessment.
RESULTS
Participant Flow
In total, 417 patients were enrolled; 3 of them were
excluded because they did not meet the inclusion
criteria after medical record veriﬁcation. Thus, 414
patients were randomly assigned to the study groups.
Nine patients were randomly assigned but withdrew
consent before initiating treatment, leaving 405 who
received the study drugs. One patient was lost to59
Figure 1. Randomization and flow of patients.
Zhang et alfollow-up and missed the ﬁrst assessment of the pri-
mary outcome measure. The number of participants
included in the full analysis set was 404. A total of
383 (92.5%) patients completed 24 weeks of study
drugs and assessments. Three (0.7%) patients were
dismissed from the study early because of treatment
failure (doubling of proteinuria). Twenty-six (6.2%)
patients were lost to follow-up (Fig 1).
Baseline Data
Age, sex, history, height, weight, systolic blood
pressure (SBP), diastolic blood pressure (DBP), 24-
hour proteinuria, serum creatinine level, eGFR, and
pathologic classiﬁcations of the 3 groups were com-
parable before treatment (P . 0.05; Table 1).
Outcome Evaluation
Primary Outcome Measure: 24-Hour Proteinuria
After 12 weeks of treatment, mean reductions from
baseline in 24-hour proteinuria in the A manihot,
losartan, and combined treatment groups were 283,
258, and 290 mg and rates of decline were 23%, 21%,
and 28%, respectively. The 24-hour proteinuria level60in all 3 groups decreased signiﬁcantly (P , 0.001).
Changes in proteinuria level among the 3 groups were
not signiﬁcantly different after 12 weeks of treatment
(P . 0.05). After 24 weeks of treatment, mean re-
ductions from baseline in 24-hour proteinuria in the A
manihot, losartan, and combined treatment groups
were 508, 376, and 545 mg and rates of decline were
47%, 33%, and 51%, respectively. The 24-hour pro-
teinuria level in all 3 groups decreased signiﬁcantly
(P , 0.001). Declines in proteinuria levels in the A
manihot and combined treatment groups were higher
than that in the losartan group (P , 0.05). Declines in
proteinuria levels between the A manihot and com-
bined treatment groups were not signiﬁcantly
different (P . 0.05). Results are shown in Table 2.
Secondary Outcome Measures
Estimated GFR. After 24 weeks of treatment, mean
increase from baseline in eGFR in the Amanihot group
was 1 mL/min/1.73 m2.Mean reductions frombaseline
in eGFRs were 3 and 1 mL/min/1.73 m2 in the losartan
and combined treatment groups, respectively. The
3 groups did not show signiﬁcant changes in eGFRsAm J Kidney Dis. 2014;64(1):57-65
Table 1. Baseline Participant Characteristics by Treatment Group
A manihot (n 5 133) Losartan (n 5 135) Combined Treatment (n 5 136) P
Age (y) 37.3 6 12.5 38.16 12.7 37.16 11.1 0.9
Sex 0.6
Male 67 (50.4) 72 (53.3) 64 (47.1)
Female 66 (50.0) 63 (46.7) 72 (52.9)
Pathologic classification 0.5
IgAN 60 (45.1) 76 (56.3) 72 (52.9)
Non-IgAN mesangial proliferative GN 35 (26.3) 28 (20.7) 34 (25.0)
FSGS 18 (13.5) 16 (11.9) 10 (7.4)
Minimal-change nephropathy 9 (6.8) 6 (4.44) 10 (7.4)
Membranous nephropathy 10 (7.5) 8 (5.9) 7 (5.2)
Mesangial proliferative GN 1 (0.8) 0 (0.0) 0 (0.0)
Other 0 (0.0) 1 (0.7) 3 (2.2)
SBP (mm Hg) 120.26 8.6 120.76 8.2 121.06 7.8 0.7
DBP (mm Hg) 74.06 6.0 74.9 6 5.6 74.7 6 5.6 0.4
24-h proteinuria (mg) 1,0456 420 1,0846 453 1,0736 439 0.9
Serum creatinine (mg/dL) 0.80 6 0.22 0.826 0.21 0.816 0.23 0.4
eGFR (mL/min/1.73 m2) 1086 24 1066 23 1066 24 0.8
Note: Values for categorical variables are given as number (percentage); values for continuous variables, as mean 6 standard
deviation. Conversion factor for serum creatinine in mg/dL to mmol/L, 388.4.
Abbreviations and definitions: A manihot, Abelmoschus manihot; DBP, diastolic blood pressure; eGFR, estimated glomerular
filtration rate; FSGS, focal segmental glomerulosclerosis; GN, glomerulonephritis; IgAN, immunoglobulin A nephropathy; other,
pathologic manifestation was glomerular ischemia associated with tubulointerstitial damage; SBP, systolic blood pressure.
RCT of Abelmoschus manihotafter treatment (P . 0.05). Differences among the
3 groups were not signiﬁcant (P . 0.05; Table 3).
Serum creatinine level. After 24 weeks of treat-
ment, mean reduction from baseline in serum creati-
nine level in the A manihot group was 0.005 mg/dL.
Mean increases from baseline in serum creatinine
levels were 0.03 and 0.01 mg/dL in the losartan
and combined treatment groups, respectively. The
3 groups did not show signiﬁcant changes in serum
creatinine levels after treatment (P . 0.05). Differ-
ences among the 3 groups were not signiﬁcant
(P . 0.05; Table 3).
Blood Pressure
After 24 weeks of treatment, SBPs were 119.56 8.5,
118.86 8.8, and 118.56 8.6 mmHg in the Amanihot,
losartan, and combined treatment groups, respectively.
DBPswere 72.96 5.8, 72.76 5.4, and 73.46 5.3 mm
Hg, respectively. Eighteen patients were given calcium
channel blockers for blood pressures $ 130/80 during
the treatment period (Amanihotgroup, 9; losartan group,
3, and combined treatment group, 6).
SBPs and DBPs in the losartan and combined
treatment groups were signiﬁcantly lower after treat-
ment (SBP: P 5 0.004 and P , 0.001; DBP:
P , 0.001 and P 5 0.02, respectively). SBPs and
DBPs in the A manihot group were not signiﬁcantly
different after treatment (P . 0.05). Change in SBP
showed a signiﬁcant difference between the A man-
ihot and combined treatment groups (P 5 0.02). TheAm J Kidney Dis. 2014;64(1):57-65other SBPs and DBPs among the groups were not
statistically signiﬁcant (P . 0.05).
Safety Evaluation
Adverse events occurred in 9 patients (14 cases) in
the A manihot group, for an incidence of 6.7%; in 10
patients (11 cases) in the losartan group, for an inci-
dence of 7.4%; and in 11 patients (15 cases) in the
combined treatment group, for an incidence of 8.1%.
There were no severe adverse events in any of the
3 groups. Rates of adverse eventswere not signiﬁcantly
different among the 3 groups (P . 0.05; Table 4).
Subgroup Analysis
The most common pathologic diagnosis in this study
was IgAN (51.5%). Therefore, subgroup analysis
restricted to patients with IgAN was performed and
results were not different from those in the overall group
(Tables S1 and S2, available as online supplementary
material).
DISCUSSION
Traditional Chinese medicine is the most distinc-
tive and widely used therapy for CKD in China and
other Asian countries. The efﬁcacy of Chinese med-
icine has been conﬁrmed in some randomized
controlled studies in recent years.7 In our study,
patients with primary glomerular disease, non–
nephrotic-range proteinuria, normal kidney function,
and well-controlled blood pressure who were given A
manihot had signiﬁcant reductions in proteinuria and61
Table 2. Change From Baseline in 24-Hour Proteinuria Over 24-Week Follow-up Period
A manihot
(n 5 133)
Losartan
(n 5 135)
Combined
Treatment
(n 5 136)
A manihot vs
Losartan
Combined
Treatment vs
A manihot
Combined
Treatment vs
Losartan
0 wk 1,0456 420 1,0846 453 1,0736 439 P 5 0.9 P5 0.9 P5 0.9
12 wk 762 6 533 825 6 706 7836 658 P 5 0.7 P5 0.7 P5 0.5
D 24-h proteinuria 22836 553 22586 701 22906 542 225 (2177 to 128)
P 5 0.9
27 (2124 to 139)
P5 0.8
232 (2118 to 181)
P5 0.8
Comparison
within group
P, 0.001 P , 0.001 P , 0.001
24 wk 5376 409 7086 588 5296 509 P5 0.02 P5 0.4 P , 0.001
D 24-h proteinuria 25086 457 23766 577 25456 500 2132 (2257 to 27)
P 5 0.003
236 (2151 to 79)
P5 0.3
2169 (2298 to 239)
P , 0.001
Comparison
within group
P, 0.001 P , 0.001 P , 0.001
Note: The 24-hour proteinuria (mg) and changes in 24-hour proteinuria from baseline (mg) in 3 groups are given as mean6 standard
deviation. Differences of change in proteinuria between groups are given as mean (95% confidence interval).
Abbreviation: A manihot, Abelmoschus manihot.
Zhang et alpreservation of kidney function. Interestingly, A
manihot showed a better therapeutic effect on
reducing proteinuria than losartan (50 mg/d) after
24 weeks of treatment. In addition, the combination
of A manihot and losartan showed better efﬁcacy than
losartan monotherapy.
Angiotensin-converting enzyme inhibitors and
ARBs are used commonly to treat proteinuria, and
the range of reduction is reportedly 30%-50% in
adults.22,23 Thus, we used losartan as the positive
control. Flowers of A manihot (Linn) Medicus (family
Malvaceae) have been used as a traditional treatmentTable 3. Change From Baseline in Serum Creatin
A manihot
(n 5 133)
Losartan
(n 5 135)
Comb
Treatm
(n 5 1
Comparison of Scr
0 wk 0.80 6 0.22 0.826 0.21 0.81 6 0
12 wk 0.81 6 0.22 0.836 0.22 0.85 6 0
24 wk 0.80 6 0.20 0.856 0.22 0.82 6 0
DScr 20.0056 0.19 10.03 6 0.18 10.016
Comparison within
group
P5 0.7 P5 0.1 P 5 0.4
Comparison of eGFR
0 wk 1086 24 1066 23 1066 2
12 wk 1086 23 1056 23 1056 2
24 wk 1096 22 1046 25 1056 2
DeGFR 11 6 20 23 6 19 216 18
Comparison within
group
P5 0.5 P5 0.1 P 5 0.0
Note: Serum creatinine and eGFR values are given as mean 6 st
respectively. Differences of change in serum creatinine and eGFR b
Abbreviations: A manihot, Abelmoschus manihot; eGFR, estimate
62of chronic glomerulonephritis in China for centuries.
Many (.20) pharmacologically active compounds
have been isolated from A manihot, including ﬂavo-
noids, organic acids, tannins, and long-chain hydro-
carbons.24 The major biologically active components
are ﬂavonoids (eg, isoquercitrin, hyperoside, hibifo-
lin, quercetin-30-O-glucoside, quercetin, and gossy-
petin).25 Metabolic proﬁles of these active
components are critical for understanding the safety
and efﬁcacy of A manihot. This herb can ameliorate
proteinuria and hematuria and improve kidney func-
tion in patients with CKD, including diabeticine and eGFR Over 24-Week Follow-up Period
ined
ent
36)
A manihot vs
Losartan
Combined
Treatment vs
A manihot
Combined
Treatment vs
Losartan
.23 P5 0.4 P 5 0.6 P5 0.8
.25 P5 0.4 P 5 0.07 P5 0.3
.24 P5 0.05 P 5 0.3 P5 0.4
0.17 20.03 (26.94 to
1.21); P 5 0.2
0.02 (22.37 to
5.47); P 5 0.4
20.02 (25.15 to
2.53); P 5 0.5
4 0.5 0.4 0.9
3 0.2 0.2 0.9
3 0.07 0.1 0.7
1.6 (21 to 9);
P 5 0.1
21.2 (28 to 2);
P5 0.2
0.02 (26 to 3);
P 5 0.9
7
andard deviation and expressed as mg/dL and mL/min/1.73 m2,
etween groups are given as mean (95% confidence interval).
d glomerular filtration rate; Scr, serum creatinine.
Am J Kidney Dis. 2014;64(1):57-65
Table 4. Summary of Adverse Events by Treatment Group
Total
A
manihot Losartan
Combined
Treatment
Dizziness 1 0 0 1
Nausea 1 1 0 0
Diarrhea 1 0 0 1
Tonsillitis 2 0 0 2
Upper respiratory tract
infection
13 4 5 4
Gingivitis 1 0 0 1
Pregnancy during treatment 1 0 1 0
Schizophrenia 1 1 0 0
Elevated white blood cell or
neutrophil count
2 0 1 1
Anemia 1 0 1 0
Thrombocytopenia 1 0 0 1
Elevated cholesterol or
triglycerides
11 5 2 4
Liver injury 4 3 1 0
Total 40 14 11 15
Abbreviation: A manihot, Abelmoschus manihot.
RCT of Abelmoschus manihotnephropathy, IgAN, membranous nephropathy, and
Henoch-Schönlein purpura nephritis.13,26-29 A mod-
ern pharmacology study found that the above-
mentioned effects of A manihot might be associated
with inhibition of immune reactions and inﬂammatory
injury, amelioration of kidney interstitial ﬁbrosis,
anticoagulant effects, and protection of kidney tubular
epithelial cells.10,30,31 However, no randomized
controlled trials have been conducted to evaluate the
efﬁcacy and safety of A manihot.
Our data show that after 12 weeks of treatment, A
manihot signiﬁcantly reduced proteinuria to the same
extent as losartan, and the efﬁcacy of the combination
of the 2 drugs was not superior to monotherapy. After
24 weeks of treatment, proteinuria with A manihot
decreased by 49%, and the effect was superior to that
of losartan; the 2-drug combination therapy was
superior to losartan monotherapy. Previous studies
have suggested that high ARB doses could delay
the progression of kidney disease in hypertensive
and/or diabetic patients.32,33 Nevertheless, according
to Shen et al,34 “in daily practice of nephrology, quite
a number of nondiabetic patients with CKD who are
normotensive do not tolerate even moderate dosages
of ARBs because of adverse effects such as systemic
hypotension, especially for Chinese patients.”34(p1,041)
This study was based on losartan at 50 mg/d as a
positive control, and one of the inclusion criteria
was effective control of hypertension (blood pressure
# 130/80 mm Hg); thus, we did not change the
losartan dosage. After 24 weeks’ treatment, blood
pressures in the A manihot and losartan groups were
not statistically different and only 9 patients in AAm J Kidney Dis. 2014;64(1):57-65manihot group and 3 patients in the losartan group
required calcium channel blockers.
In terms of kidney function, our results showed that
although not statistically signiﬁcant, serum creatinine
levels in the A manihot group nominally decreased
while eGFRs nominally increased. Changes in kidney
function in the losartan and combined treatment
groups showed the opposite trends, but comparisons
among the 3 groups indicated no signiﬁcant differ-
ences. Other research has demonstrated that A man-
ihot can signiﬁcantly reduce serum creatinine level
and protect kidney function in patients with decreased
kidney function.35,36 No study has conﬁrmed that A
manihot affects kidney function in patients with
normal serum creatinine levels and eGFRs. The change
in serum creatinine level and eGFR in the losartan
group was related to the pharmacologic effects of
renin-angiotensin-aldosterone system blockers on the
hemodynamic origin.37
A manihot and losartan generally were well toler-
ated. There were no severe adverse events or
decreases in kidney function in the A manihot group.
The overall incidence of adverse events was low and
generally similar among treatment groups. Overall, A
manihot was well tolerated with minimal adverse
events. Since the huangkui capsule acquired national
approval from the China Food and Drug Adminis-
tration in 1999, there have been no reports of severe
adverse events. The most common adverse event is
mild to moderate gastrointestinal discomfort.38
This trial has some limitations. The ﬁrst limitation
is that the patients enrolled in this study had mild
kidney disease and those with nephrotic syndrome
were excluded. In addition, this study did not include
patients with secondary glomerular diseases. Other
studies have shown that A manihot has good efﬁcacy
in patients with nephrotic syndrome and diabetic
nephropathy.14,39-41 The short follow-up time is an
additional limitation.
In conclusion, A manihot can reduce proteinuria
levels of patients with CKD stages 1-2 with primary
glomerular disease and has better efﬁcacy than los-
artan (50 mg/d). In addition, A manihot can maintain
stable kidney function. Despite the need for long-term
studies, results of this study provide initial evidence
for the efﬁcacy and safety of A manihot in the treat-
ment of early CKD with low to moderate proteinuria.
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